tumor necrosis factor receptor 2 -targeting monoclonal antibodies (Boston Immune Technologies & Therapeutics/Massachusetts General Hospital/Harvard Medical School)

N/A

Report date: 2025/03/20 10:03:55

Base Information

Drug Nametumor necrosis factor receptor 2 -targeting monoclonal antibodies (Boston Immune Technologies & Therapeutics/Massachusetts General Hospital/Harvard Medical School)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 1B antagonists

TargetsTumor necrosis factor receptor superfamily member 1B

Therapy Area/IndicationsCommunicable Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe General Hospital Corporation D/B/A Massachusetts General Hospital

China Registration ClassN/A

Develop Information

Active CompaniesBoston Immune Technologies & Therapeutics

Inactive CompaniesThe General Hospital Corporation D/B/A Massachusetts General Hospital Harvard Medical School

Active IndicationsCommunicable Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A